Oncolytic viruses as novel anticancer agents: turning one scourge against another.
Although the use of viruses as oncolytic agents is an historic concept, the use of genetically modified viruses to selectively target tumour cells is relatively novel and recent. The ability of viruses to efficiently infect and lyse cells, combined with the potential augmentation of this effect by progeny viruses throughout the tumour provide justification for exploitation of these agents in cancer therapy. Before application to humans, though, issues related to tumour cell selectivity, lack of toxicity to normal tissues and the effect of the antiviral immune response, will have to be clarified. The more commonly used oncolytic viruses are based on mutant strains of herpes simplex virus, adenovirus and reovirus. The tumour selectivity of each of these strains is discussed, particularly the complementation of the viral defect by cellular pathways involved in tumourigenesis. The combination of oncolytic viruses with radiation, chemotherapy and gene therapy is also reviewed. Further study of the interaction of viral proteins with cellular pathways involved in cell cycle control will provide the rationale for viral mutants with increased selectivity for tumour cells.
Smith
E R
ER
Molecular Neuro-oncology Laboratories, Neurosurgery Service, Massachusetts General Hospital, CNY6, 13th Street, Charlestown, MA 02119, USA.
Chiocca
E A
EA
D000256:Adenoviridae; D000818:Animals; D000970:Antineoplastic Agents; D017209:Apoptosis; D019496:Cancer Vaccines; D002453:Cell Cycle; D003131:Combined Modality Therapy; D015870:Gene Expression; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D012087:Reoviridae; D018139:Simplexvirus; D014764:Viral Proteins
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D014764:Viral Proteins